Organization | Hermann Eye Center

Hermann Eye Center Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Founded: Houston TX United States (1977)

Organization Overview

First Clinical Trial

2003

NCT00121147

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Alternative names

Hermann Eye Center

Active Ingredients

Drugs in Phase 4 Trials (1)

cyclosporine (sandimmune) (1 trial)

Drugs in Phase 2 Trials (2)

bevacizumab (avastin) (1 trial)

mitomycin (mutamycin) (1 trial)

Drugs in Phase 1 Trials (1)

pegaptanib (macugen) (1 trial)

Drugs in Other Trials (5)

brimonidine (alphagan) (1 trial)

brinzolamide (azopt) (1 trial)

lidocaine (xylocaine) (1 trial)

tetracaine (pontocaine) (1 trial)

travoprost (travatan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dry Eye Syndromes (Phase 4)

Eye Diseases (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Pterygium (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 9